Business Context and Reporting Period
Kodiak Sciences Inc. (KOD) is a pre-commercial, retina-focused biotechnology company developing transformative therapeutics for retinal diseases. The company operates as a single segment and is currently in the clinical stage of drug development with no products approved for commercial sale. This summary covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(65.6) million | $(54.3) million | $(123.8) million | $(111.8) million |
| Net Loss Per Share | $(1.05) | $(1.03) | $(1.99) | $(2.12) |
| Operating Expenses | $66.8 million | $55.5 million | $126.6 million | $114.6 million |
| Cash and Cash Equivalents | $125.9 million (as of June 30, 2026) | |||
| Accumulated Deficit | $(1.68) billion (as of June 30, 2026) | |||
| Net Cash Used in Operating Activities | N/A | $(86.2) million | $(63.8) million |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by $13.3 million (31%) in Q2 2026 compared to Q2 2025, and by $18.2 million (21%) on a year-to-date basis. This increase was driven by ramped-up manufacturing and clinical trial costs for KSI-501 and KSI-101 programs.
- Decreased G&A: General and administrative expenses decreased by $2.0 million in Q2 2026 and $6.2 million YTD 2026. Reductions were attributed to lower stock-based compensation, reduced net rent expense following a sublease, and the absence of a non-recurring $1.9 million lease impairment expense recorded in Q1 2025.
- Cash Burn: Net cash used in operating activities increased to $86.2 million for the six months ended June 30, 2026, compared to $63.8 million in the prior year period.
Guidance, Outlook, and Risks
Going Concern Warning
Management has stated that existing cash and cash equivalents may not be sufficient to meet anticipated operating and capital expenditure requirements for the 12 months following the report date. Consequently, there is substantial doubt regarding the Company's ability to continue as a going concern. The company plans to raise additional capital through equity or debt financings, collaborations, or a combination thereof.
Clinical Pipeline Updates
- Zenkuda (tarcocimab): Topline data for the Phase 3 DAYBREAK study (wet AMD) is expected in September 2026. The company intends to file a Biologics License Application (BLA) in 2026 for diabetic retinopathy, retinal vein occlusion, and wet AMD.
- KSI-501: Topline data for the Phase 3 DAYBREAK study is expected in September 2026. The Phase 3 ALTO study in diabetic macular edema (DME) initiated enrollment in August 2026.
- KSI-101: Topline results for the first cohort of the Phase 3 PEAK trial are expected in December 2026. Enrollment for the second pivotal cohort is expected to complete in Q4 2026.
Key Risks
- Capital Requirements: Failure to secure additional financing could force the company to pause, scale back, or discontinue development programs.
- Clinical Uncertainty: The company has previously failed to meet primary efficacy endpoints in Phase 3 trials (GLEAM/GLIMMER). Future trials carry significant risk of failure.
- Manufacturing: Reliance on third-party manufacturers (Lonza) and complex supply chains for raw materials.
Investor Verification Checklist
- Verify the sufficiency of the $125.9 million cash balance against the projected burn rate and the timeline for the next financing round.
- Monitor the September 2026 topline data release for the DAYBREAK study (Zenkuda and KSI-501) as a critical catalyst for BLA filing.
- Review the specific terms of any new financing agreements for potential dilution or restrictive covenants.
- Assess the impact of the July 2026 lease termination and sublease adjustments on future facility costs.
- Confirm the status of the Phase 3 PEAK and PINNACLE trials for KSI-101, specifically enrollment rates and safety data.